Abstrait

Potential Pharmacological Therapies for Patients with Renal Disease Affected by Coronavirus Disease-19

Jie Liu*

Due to renal dysfunction and pre-existing comorbidities, people with chronic kidney disease (CKD), including dialysis and transplant recipients, are more likely to catch SARSCoV-2. There is currently no recognised protocol for treating these COVID-19-infected high-risk patients. Since most of the medications used to treat COVID-19 are currently experimental, the authors’ goal is to inform readers about dose modifications for kidney failure at various stages and significant renal side effects. We conducted a non-systematic review of the COVID-19 medications already on the market by using a number of different clinical trial databases and search engines. When treating COVID-19, a number of antivirals and monoclonal antibodies need to have their dosages adjusted. Nephrologists must carefully evaluate the adverse effects of various treatment combinations in a pandemic environment to determine the right dosage based on renal function and to provide the best therapeutic impact while preventing further renal damage. To ascertain the security and effectiveness of these medications in renal patients, additional research is necessary